FDA Clears Samus Drug for Glioma Phase Ib Study

FDA Clears Samus Drug for Glioma Phase Ib Study

Source: 
BioSpace
snippet: 

The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for PU-AD (icapamespib), an epichaperome inhibitor for recurrent malignant glioma developed by privately held biopharmaceutical company Samus Therapeutics.